The use of desmoteplase (bat saliva) in the treatment of ischaemia.
In an era of ageing global populations and accumulation of cardiovascular risk factors, the importance of reperfusion/recanalisation therapies in treating vascular occlusive disease is growing. There are multiple thrombolytic agents available, including bat saliva-derived plasminogen activator. A peer reviewed literature search was conducted and focus was on the data on the use of desmoteplase in the treatment of ischaemic stroke. Currently, there is not enough evidence for clinical use in ischaemic stroke and further Phase III studies are underway. At this stage, desmoteplase remains an investigational compound.